PMID- 22649281
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20220408
IS  - 1178-7023 (Electronic)
IS  - 1178-7023 (Linking)
VI  - 5
DP  - 2012
TI  - Efficacy of esomeprazole in treating acid-related diseases in Japanese 
      populations.
PG  - 49-59
LID - 10.2147/CEG.S23926 [doi]
AB  - Esomeprazole (Nexium((R)); AstraZeneca), the S-isomer of omeprazole, is the first 
      proton pump inhibitor (PPI) to be developed as an optical isomer. Compared with 
      omeprazole, esomeprazole has an improved pharmacokinetic profile with regards to 
      CYP2C19 (S-mephenytoin 4'-hydroxylase) genotype, showing increased systemic 
      exposure and less interindividual variability. Further, esomeprazole is a more 
      potent acid inhibitor than other currently available PPIs and is therefore used 
      as a first-line drug for acid-related diseases. While esomeprazole has been 
      available in a number of countries worldwide, the compound only received 
      authorized permission to be marketed in Japan in September 2011. The standard 
      esomeprazole dose in Japan for the treatment of peptic ulcers and 
      gastroesophageal reflux disease (GERD) is 20 mg. Other advised dosages are 10 mg 
      for nonerosive reflux disease and 20 mg twice-daily dosing for eradication of 
      Helicobacter pylori. In Japanese, the effective rate of esomeprazole 20 mg during 
      24 weeks for GERD patients is 92.0% (88.0%-96.0%), while the prevention of peptic 
      ulcer development using 20 mg for 24 weeks in patients treated with nonsteroidal 
      anti-inflammatory drugs is 96.0% (92.8%-99.1%). Although clinical data are 
      limited, the usefulness of esomeprazole is expected in Japanese subjects given 
      the reduced prevalence of CYP2C19 rapid metabolizers in Japan compared with 
      Western countries.
FAU - Sugimoto, Mitsushige
AU  - Sugimoto M
AD  - First Department of Medicine, Hamamatsu University School of Medicine, Shizuoka, 
      Japan.
FAU - Furuta, Takahisa
AU  - Furuta T
LA  - eng
PT  - Journal Article
DEP - 20120514
PL  - New Zealand
TA  - Clin Exp Gastroenterol
JT  - Clinical and experimental gastroenterology
JID - 101532800
PMC - PMC3359912
OTO - NOTNLM
OT  - CYP2C19
OT  - GERD
OT  - H. pylori
OT  - PPI
OT  - esomeprazole
OT  - peptic ulcer
EDAT- 2012/06/01 06:00
MHDA- 2012/06/01 06:01
PMCR- 2012/05/14
CRDT- 2012/06/01 06:00
PHST- 2012/06/01 06:00 [entrez]
PHST- 2012/06/01 06:00 [pubmed]
PHST- 2012/06/01 06:01 [medline]
PHST- 2012/05/14 00:00 [pmc-release]
AID - ceg-5-049 [pii]
AID - 10.2147/CEG.S23926 [doi]
PST - ppublish
SO  - Clin Exp Gastroenterol. 2012;5:49-59. doi: 10.2147/CEG.S23926. Epub 2012 May 14.